The Competition Commission of India (CCI) has granted approval for the acquisition of the remaining 30% equity stake in Signet Excipients Private Limited by IMCD India Private Limited. The proposed combination involves IMCD India exercising a call option to secure the additional equity stake in Signet Excipients, a move that has now received regulatory clearance.
IMCD India Private Limited, an indirect wholly-owned subsidiary of Dutch entity IMCD N.V., operates from Mumbai, India. It specializes in the sales, marketing, and distribution of specialty chemicals, covering various segments such as pharmaceutical excipients, food and nutrition ingredients, coatings, construction chemicals, advanced materials, lubricants, fuels chemicals, textiles, and beauty and personal care ingredients within the Indian market.
Signet Excipients Private Limited, under joint control by IMCD and its promoters, focuses on the sales, marketing, distribution, importing, or exporting of excipients primarily used in pharmaceuticals, nutraceuticals, biotech, food, API products, and other related items for pharmaceutical formulation. The approval from CCI marks a significant step forward in IMCD India’s acquisition strategy, solidifying its position in the market.
